Trialssemaglutidenovo nordiskdiabetic retinopathytype 2 diabetes

Novo Nordisk's five-year semaglutide retinopathy trial listed as active, not recruiting

FOCUS, begun in May 2019, randomizes type 2 diabetes patients to weekly injected semaglutide or placebo on top of existing diabetes medicines.

By Priya Raman · Science Reporter

Oct 7 08:00 ETSource: ClinicalTrials.gov

The wire

01ClinicalTrials.gov entry NCT03811561, a Phase 3 Novo Nordisk study of long-term semaglutide effects on diabetic retinopathy, is now listed as active and no longer recruiting, with a five-year duration.
02Diabetic retinopathy progression has been a labeling question for semaglutide since SUSTAIN-6, so the readout matters for prescribers managing patients with eye disease.
03No results are posted; the trial is sponsor-run and the registry record gives no completion date or interim data.

From the source

A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
NCT03811561 · PHASE3 · ACTIVE NOT RECRUITING · Sponsor: Novo Nordisk A/S · Conditions: Diabetes Mellitus, Type 2.

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT03811561